CRISPR Q1 2026: net loss narrows to $122.9M; CASGEVY revenue $43M; cash at $2.44B

CRISPR Therapeutics AG

2026-Q1 EPS reported -$1.28 revenue$1,458,000

Net loss of $122.9M vs $136.0M in Q1 2025; R&D spend $68.6M, G&A $17.2M.
CASGEVY revenue of $43M; collaboration expense net $45.9M, down on higher revenue share.
Cash, equivalents and securities $2,441.8M, up from $1,975.8M, boosted by $585.4M convertible note.
Zugo-cel started 3rd Phase 1 in autoimmune neurology; SLE patients remain in DORIS remission at Month 12 and Month 6.
In vivo CTX310 IND cleared for US; CTX460 (AATD) and CTX340 (hypertension) on track for mid-2026 and H1 2026 clinical starts.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

CRISPR Therapeutics AG reported first quarter 2026 results: revenue $43 million.

Period: first quarter 2026
Revenue: $43 million
Result: reported results

Exact text from the filing

CASGEVY generated first quarter 2026 revenue of $43 million.

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

CRISPR Therapeutics AG filing history →

Source: SEC EDGAR

accession 0001193125-26-204147

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.